Table 1. Summary of included studies.

First author [ref.]	Study name	Study design	Study location	Intervention	Comparator
Konstan [15]	EAGER trial	RCT, open-label, non-inferiority trial (n=533) Duration: 24 weeks	127 centres in 15 countries (including North America, Europe, Australia, Israel and Latin America)	Tobramycin dry powder T-326 Inhaler, 112 mg twice daily; 28 days on followed by 28 days off treatment	Tobramycin solution PARI LC Plus jet nebuliser, 300 mg/5 mL twice daily; 28 days on followed by 28 days off treatment
Konstan [13]
Novartis Pharmaceuticals [16]
European Medicines Agency [18]
Forest Laboratories Ltd [17]	COLO/DPI/02/06	RCT, open-label, non-inferiority trial (n=380) Duration: 24 weeks	66 centres in European Union countries, and Russia and the Ukraine	Colistimethate sodium dry powder Turbospin device, 125 mg twice daily; continuous treatment	Tobramycin solution PARI LC Plus jet nebuliser, 300 mg/5 mL twice daily; 28 days on followed by 28 days off treatment
European Medicines Agency [1]
Forest Laboratories Ltd [17]	COLO/DPI/02/05	RCT, open-label with crossover (n=16) Duration: 8 weeks	3 centres in the UK	Colistimethate sodium dry powder Turbospin device, 125 mg twice daily; continuous treatment	Colistimethate sodium solution (device not reported), 2 MU twice daily; continuous treatment

RCT: randomised controlled trial.